<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04976348</url>
  </required_header>
  <id_info>
    <org_study_id>NL76585.068.21</org_study_id>
    <nct_id>NCT04976348</nct_id>
  </id_info>
  <brief_title>The Maastricht Cardiomyopathy Registry</brief_title>
  <acronym>mCMP-registry</acronym>
  <official_title>The Maastricht Cardiomyopathy Registry (mCMP-registry): Improving (Early) Diagnosis and Optimizing Risk Stratification Across the Cardiomyopathy Spectrum</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Maastricht cardiomyopathy registry (mCMP-registry) is an prospective observational&#xD;
      registry including multi-omics (diagnostic) measurements performed as part of routine&#xD;
      clinical care, bio-banking (optional), and yearly questionnaires (optional).&#xD;
&#xD;
      It's objective is to optimize (early) diagnosis and risk-stratification of (early)&#xD;
      cardiomyopathy phenotypes and to create a better understanding of underlying&#xD;
      pathophysiological processes&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale: Heart failure (HF) represents a heterogeneous range of clinical overlapping&#xD;
      cardiomyopathy phenotypes, resulting from multifactorial environmental insults in the&#xD;
      presence or absence of a genetic predisposition. A better understanding of (early)&#xD;
      cardiomyopathy phenotypes, their underlying pathophysiological processes, and their related&#xD;
      disease burden is key to pave the way for novel preventive and/or intervention studies.&#xD;
&#xD;
      Objective: To optimize (early) diagnosis and risk-stratification of (early) cardiomyopathy&#xD;
      phenotypes and to create a better understanding of underlying pathophysiological processes.&#xD;
&#xD;
      Study design: The Maastricht cardiomyopathy registry (mCMP-registry) is an&#xD;
      investigator-initiated single center (Maastricht University Medical Center, MUMC+)&#xD;
      prospective observational registry including multi-omics (diagnostic) measurements performed&#xD;
      as part of routine clinical care, bio-banking (optional), and yearly questionnaires&#xD;
      (optional).&#xD;
&#xD;
      Study population: All subjects aged ≥16 years referred to the cardiology outpatient clinic of&#xD;
      the MUMC+ for heart failure like symptoms (as stated in the ESC 2016 Guidelines) and/or for&#xD;
      cardiac screening are eligible for inclusion.&#xD;
&#xD;
      Main study parameters/endpoints: This is a prospective registry from which multiple research&#xD;
      questions can be answered. In general, two main approaches will be used: (A) a data-driven&#xD;
      (multi-)omics approach which aims to identify clusters of patients to predict clinical&#xD;
      outcome, to improve (early) diagnosis, and/or to identify clusters of patients that share&#xD;
      underlying pathophysiological processes; (B) a hypothesis-driven approach in which clinical&#xD;
      parameters are tested for their (incremental) diagnostic and/or prognostic value.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">August 2021</start_date>
  <completion_date type="Anticipated">December 2051</completion_date>
  <primary_completion_date type="Anticipated">December 2051</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>15 Years</target_duration>
  <primary_outcome>
    <measure>(sudden) cardiac death or heart transplantation</measure>
    <time_frame>through study completion, an average of 15 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Heart Failure hospitalization</measure>
    <time_frame>through study completion, an average of 15 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Life-threatening arrhythmias</measure>
    <time_frame>through study completion, an average of 15 years</time_frame>
    <description>justified implantable cardioverter-defibrillator shock, justified anti-tachypacing therapy, cardiac arrest, hemodynamic unstable ventricular tachycardia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life EQ-5D questionnaire</measure>
    <time_frame>through study completion, an average of 15 years</time_frame>
    <description>EQ-5D questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Economic burden</measure>
    <time_frame>through study completion, an average of 15 years</time_frame>
    <description>institute for Medical Technology Assessment (iMTA) Productivity Cost Questionnaire (iPCQ) and iMTA Medical Consumption Questionnaire (iMCQ)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Age</measure>
    <time_frame>through study completion, an average of 15 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Sex</measure>
    <time_frame>through study completion, an average of 15 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Body mass index</measure>
    <time_frame>through study completion, an average of 15 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Underlying pathogenic</measure>
    <time_frame>through study completion, an average of 15 years</time_frame>
    <description>variants found in cardiac associated genes</description>
  </other_outcome>
  <other_outcome>
    <measure>Medication usage</measure>
    <time_frame>through study completion, an average of 15 years</time_frame>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">10000</enrollment>
  <condition>Heart Failure</condition>
  <condition>Cardiomyopathies</condition>
  <arm_group>
    <arm_group_label>Consenting participants</arm_group_label>
    <description>All subjects aged ≥16 years referred to the cardiology outpatient clinic of the MUMC+ for heart failure like symptoms (as stated in the ESC 2016 Guidelines) and/or for cardiac screening are eligible for inclusion.</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood, urine and cardiac biopsy samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All subjects aged ≥16 years referred to the cardiology outpatient clinic of the MUMC+ for&#xD;
        heart failure like symptoms (as stated in the ESC 2016 Guidelines) and/or for cardiac&#xD;
        screening are eligible for inclusion.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Referred to the cardiology outpatient clinic of the MUMC+ for heart failure like&#xD;
             symptoms (as stated in the ESC 2016 Guidelines(3)) or for cardiac screening;&#xD;
&#xD;
          -  Age ≥16 years.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unwillingness to participate or unable to give written informed consent (e.g. due to&#xD;
             language barriers or severe intellectual disability).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jerremy Weerts, MD</last_name>
    <phone>+ 31 43 3871592</phone>
    <email>jerremy.weerts@mumc.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Maastricht UMC+</name>
      <address>
        <city>Maastricht</city>
        <state>Limburg</state>
        <zip>6229HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jerremy Weerts</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 22, 2021</study_first_submitted>
  <study_first_submitted_qc>July 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2021</study_first_posted>
  <last_update_submitted>August 17, 2021</last_update_submitted>
  <last_update_submitted_qc>August 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>heart failure</keyword>
  <keyword>registry</keyword>
  <keyword>cardiomyopathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

